Improvements in the management of prostate cancer have increased the need to consider patients’ quality of life, in particular in relation to sexual function. The causes of sexual dysfunction are varied and derive from both the condition and its management. Health professionals must choose their treatment strategies with great care. Patient expectations must be understood, and patients should be offered counselling, as an understanding of what can reasonably be expected contributes to patients’ perception of their quality of life. There are few studies on sexual dysfunction in patients with prostate cancer. A first step would be to develop reliable questionnaires for the assessment of the problem. This article describes and discusses the findings of one such recently developed questionnaire. When baseline measures of sexual function have been established and the extent of sexual dysfunction in patients with prostate cancer is reliably quantified, large multicentre trials can be performed to evaluate the impact of different therapies on sexual function and quality of life. Sexual dysfunction is an area which will be of increasing importance to urologists who manage prostate cancer and one that should not be underestimated.

1.
Walsh PC, Lepor H, Eggleston JC: Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate 1983;4:473–485.
2.
Meuleman EJ, Diemont WL: Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction. Urol Clin North Am 1995;22:803–819.
3.
Walsh PC, Donker PJ: Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982;128:492–497.
4.
Jenkins AD, Turner TT, Howards SS: Physiology of the male reproductive system. Urol Clin North Am 1978;5:437–450.
5.
Meuleman EJ: Diagnosis of erectile dysfunction; in Krane RJ, Siroky MB, Fitzpatrick JM (eds): Clinical Urology. Philadelphia, Lippincott, 1994, pp 1217–1233.
6.
Nehra A, Ramakumar S, McKusick MA, Lewis TW, Barrett DM, Myers RP: Pharmaco-angiographic prevalence of accessory pudendal arteries: Role in maintaining sexual function following radical retropubic prostatectomy? (abstract 1396). J Urol 1997;157:357.
7.
Goldstein I, Feldman M, Deckers PJ, Krane, RJ: Radiation associated impotence: A clinical study of its mechanism. JAMA 1984;1251:9031.
8.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB: Impotence and its medical and psychosocial correlates: Results of the Massachusetts male ageing study. J Urol 1994;151:54–57.
9.
Fossa SD, Woehre H, Kurth KH, Hetherington J, Bakke H, Rustad DA, Skanvik R: Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997;31 (suppl 3):3–80.
10.
Helgason AR: Prostate Cancer Treatment and Quality of Life: A Three Level Epidemiological Approach; thesis, University of Stockholm, 1997.
11.
Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Steinck G: Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997;158:155–159.
12.
Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G: Waning sexual function: The most important disease specific distress for patients with prostate cancer. Br J Cancer 1996;73:1417–1421.
13.
Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Gothberg M, Steineck G: Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: A population-based study. Age Ageing 1996;25:285–291.
14.
Helgason AR, Arver S, Adolfsson J, Dickman P, Granath F, Steineck G: ‘Potency’. The validation of information from a self-administrated questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol 1998;81:135–141.
15.
Pedersen KV, Carlsson P, Rahmquist M, Varenhorst E: Quality of life after radical prostatectomy for carcinoma of the prostate. Eur Urol 1993;24:7–11.
16.
Helgason AR, Fredrikson M, Adolfsson J, Steineck G: Decreased sexual capacity after radiation therapy for prostate cancer impairs quality of life. Int J Radiat Oncol Biol Phys 1995;32:33–39.
17.
Fransson P, Widmark A: Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Cancer 1996;78:1066–1078.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.